Introduction {#s1}
============

Stage III non-small cell lung cancer (NSCLC) is a heterogeneous disease and surgical resection with or without neoadjuvant therapy could be carried out in selected patients ([@B1], [@B2]). After curative resection, disease recurrence poses a considerable threat and it has been demonstrated that platinum-based adjuvant chemotherapy could significantly reduce postoperative recurrence and improve 5-year survival ([@B3], [@B4]). However, although numerous retrospective studies and several population-based investigations ([@B5]--[@B9]) have suggested a beneficial role of postoperative radiotherapy (PORT) in reducing loco-regional recurrence (LRR), prolonging disease-free survival (DFS) and even improving overall survival (OS) among patients with completely resected (y)pN2 NSCLC ([@B5], [@B10], [@B11]), the clinical value of PORT is still controversial due to a lack of convincing data from large randomized clinical trials ([@B12], [@B13]).

Moreover, there is no definite agreement on the delineation of clinical target volume (CTV) during PORT for completely resected (y)pN2 NSCLC, and it varies between different institutions and clinical trials ([@B14], [@B15]). The rationales of CTV delineation are mostly based on the patterns of disease recurrence in surgical resected patients who don\'t receive PORT and patterns of treatment failure in those who receive PORT. In these studies, cumulative incidence, anatomic locations, and risk factors of LRR were extensively examined. However, the definitions of LRR are different, some of which include the initial disease recurrence developed in the supraclavicular region (SCR) ([@B9], [@B16]), while others don\'t ([@B7], [@B17]). Investigations specifically focused on SCR are seldom reported and elective supraclavicular nodal irradiation (ESRT) is not routinely performed.

In the current study, we investigated the cumulative incidence, risk factor, and prognostic significance of SCR in completely resected (y)pN2 NSCLC. Additionally, our recent study finds crucial prognostic value of routine immunohistochemical (IHC) markers in completely resected NSCLC ([@B18]). Hence, besides common clinic-pathological variables, a list of routine IHC markers were examined when investigating the risk factors of SCR.

Materials and Methods {#s2}
=====================

Patients
--------

Lung cancer patients who received surgery at Fudan University Shanghai Cancer Center (FUSCC) from January 2013 to December 2018 were retrospectively reviewed. Patients who underwent complete surgical resection ([@B19]), with pathologically confirmed N2 disease and received standard adjuvant chemotherapy, were included in the study. Patients received PORT or not, as well as neoadjuvant chemotherapy or not, were both allowed to be included. Exclusion criteria included a second primary tumor, compromised resection, positive surgical margins, neoadjuvant radiotherapy, receiving no adjuvant chemotherapy, death due to surgical complications, and postoperative follow up \<3 months.

For each patient, common clinic-pathological parameters were gathered from the electronic medical records, including age, sex, smoking history, the Eastern Corporative Oncology Group (ECOG) performance score, clinical TNM stage, pathological TNM stage, primary tumor size, tumor differentiation, tumor histology, tumor location, lymphovascular invasion, visceral pleural invasion, perineural invasion, and type of surgery. Pathologic TNM stage was in accordance with the eighth edition Lung Cancer Stage Classification ([@B20]). Tumor differentiation and tumor histology were determined on the basis of the 2015 World Health Organization Classification of Tumors of the Lung, Pleura, Thymus, and Heart ([@B21]). Besides, the expression status of 12 IHC markers (i.e., HER2, TTF1, ERCC1, CK20, CK5/6, CK7, P63, NapsinA, Syn, RRM1, EGFR, and Ki67) were collected. The IHC staining and evaluation were routinely performed in the Immunohistochemistry Diagnostic Laboratory of our cancer center. Our study followed The Declaration of Helsinki. The institutional review board of FUSCC approved the study. Informed consent was waived by the institutional review board because this was a retrospective study.

Treatment
---------

Pretreatment evaluation generally included clinical assessment, blood test, bronchoscopy, contrast-enhanced chest computed tomography (CT) scan, ultrasonographic examination or CT scan of the abdomen, brain magnetic resonance imaging (MRI) and bone scans. Patients with mediastinal lymph node enlargement (\>1 cm) in the short axis on CT scan or pathologically proven to be malignant, were defined as harboring clinical N2 (cN2) disease. Of note, positron emission tomography (PET)/CT, as well as invasive staging of the mediastinum, was strongly recommended for patients with cN2 disease at our cancer center.

Neoadjuvant therapy generally consisted of 3--4 cycles of platinum-based doublet regimen and surgical treatment included lobectomy, sublobectomy, and pneumonectomy, with systematic multilevel mediastinal lymph node dissection or adequate mediastinal sampling (no \<3 N2 stations, must include the subcarinal station). PORT was performed according to our institutional protocol ([@B7]), using the intensity-modulated radiation therapy technique employing a linear accelerator with 6-MV X-rays. Briefly, the CTV for left lung cancers included the bronchial stump and 2R, 2L, 4R, 4L, 5, 6, 7, 10, and 11L lymph node stations, while the CTV for right lung cancers included the bronchial stump and 2R, 4R, 7, 10, and 11R stations. ESRT was not performed. The total radiation dose prescibed to the planning target volume (PTV) was generally 50.4 Gy, administered daily at 1.8 Gy per fraction, 5 days per week.

Follow Up
---------

Follow-ups were at the discretion of the treating physicians and were generally scheduled at regular intervals: every 3 months after surgery in the first 2 years, every 6 months for the next 3 years and annually thereafter. During follow-up, blood tests, chest CT scans, and CT scans or ultrasonographic examination of abdominal and cervical regions, were routinely performed, while brain MRI and bone scans were not mandatory. Telephone calls were also implemented when necessary.

Postoperative recurrence was diagnosed considering all the evidence provided by imaging scans and pathologic confirmation. Initial disease recurrence in the supraclavicular region was defined as SCR and first relapse developed at the surgical margin, ipsilateral hilum, and/or mediastinum was considered LRR. Initial disease recurrence beyond LRR and SCR, was categorized as distant metastasis (DM).

Pattern of Failure Analyses
---------------------------

For patients with LRR, the PTVs were restored for those who received PORT and virtual PTVs were created for those who didn\'t receive PORT by independent radiation oncologist, according to our institutional protocol mentioned above. Meanwhile, for patients with SCR, individual virtual PTVs were created for ipsilateral ESRT (PTV-sc) by independent radiation oncologist, according to the CT atlas proposed by Lynch et al. ([@B22]). Then, we plotted the sites of LRRs and/or SCRs, and overlaid them with restored or created PTVs. Coverage of the LRRs and SCRs by the PTVs were investigated.

Statistical Analyses
--------------------

Recurrence free survival (RFS) was calculated from surgery to initial disease recurrence. Overall survival (OS1) was calculated from surgery to death of any cause in the entire cohort and OS2 was calculated from initial disease recurrence to death of any cause in patients with recurrent disease. Differences between clinical parameters were compared using the χ^2^ and Fisher\'s exact tests. The predictors of SCR were selected using competing risk methodology and Stata version 13.1 software (StataCorp, College Station, TX, USA). The associations between clinic-pathological parameters and OS were identified using the Cox proportional hazard regression model. The hazard ratio (HR) and the 95% confidence interval (CI) were calculated using coefficients from the model. Kaplan--Meier method was used to estimate survival, and differences among groups were investigated by the log-rank test. Statistical analysis was performed using SPSS 21.0 (SPSS, Chicago, IL, USA). All assessment is considered to be significant when two-sided *p*-value is \<0.05.

Results {#s3}
=======

Patients Characteristics
------------------------

A total of 311 patients were finally enrolled and a flowchart for patient selection was presented in [Supplementary Figure 1](#SM1){ref-type="supplementary-material"}. Detailed baseline disease characteristics of the 311 patients were summarized in [Table 1](#T1){ref-type="table"}. The majority of patients had a histology of non-squamous NSCLC and received lobectomy. The positive rate of HER2, TTF1, ERCC1, CK20, CK5/6, CK7, P63, NapsinA, Syn, RRM1, and EGFR, was 31.8, 64.0, 39.9, 6.4, 25.4, 80.4, 38.6, 54.3, 12.5, 45.0, and 60.8%, respectively. Additionally, Ki67 ≥ 50% was detected in 43.7% of the patients. Pretreatment PET/CT was performed in 237 (76.2%) patients and invasive staging of the mediastinum was underwent in 35 (11.3%) patients. One hundred and sixty-four patients were found to have cN2 disease, among whom 148 (90.2%) patients received pretreatment PET/CT and 30 (18.3%) patients had invasive staging of the mediastinum. A total of 31 (18.9%) patients received neoadjuvant chemotherapy.

###### 

Disease characteristics.

  **Variables**                                **Number of patients (%)**
  -------------------------------------------- ----------------------------
  **Age at diagnosis (years)**                 
      ≤ 65                                     151 (48.6)
     \>65                                      160 (51.4)
  **Sex**                                      
     Female                                    127 (40.8)
     Male                                      184 (59.2)
  **Smoking history**                          
     Ever smoker                               144 (46.3)
     Never smoker                              167 (53.7)
  **ECOG performance score**                   
     0                                         252 (81.0)
     1                                         59 (19.0)
  **Clinical N stage**                         
     cN0--1                                    147 (47.3)
     cN2                                       164 (52.7)
  **Neoadjuvant chemotherapy**                 
     Yes                                       31 (10.0)
     No                                        280 (90.0)
  **Surgery type**                             
     Sublobar                                  18 (5.8)
     Lobectomy                                 276 (88.7)
     Pneumonectomy                             17 (5.5)
  **Pathological T stage**                     
     pT0--2                                    262 (84.2)
     pT3--4                                    49 (15.8)
  **Lymphovascular invasion**                  
     Absent                                    150 (48.2)
     Present                                   161 (51.8)
  **Visceral pleural invasion**                
     Absent                                    195 (62.7)
     Present                                   116 (37.3)
  **Tumor location**                           
     Left lower lobe                           44 (14.1)
     Left upper lobe                           90 (29.0)
     Right lower lobe                          53 (17.0)
     Right middle lobe                         44 (14.1)
     Right upper lobe                          80 (25.7)
  **Histology**                                
     Squamous cell carcinoma                   61 (19.6)
     Non-squamous non-small cell lung cancer   250 (80.4)

*ECOG, Eastern Corporative Oncology Group*.

Cumulative Incidence and Risk Factors of SCR
--------------------------------------------

Post surgery, 94 patients received PORT and with a median follow up of 26 (range, 3--78) months, 203 patients developed recurrent disease, including 27 SCRs. Of note, 17 of the 27 SCRs were pathologically confirmed and the rest 10 were diagnosed by clinical assessments and radiographic findings. The 1, 3, and 5-year RFS were 56.9, 23.9, and 9.0%, in patients without PORT, respectively, and were 71.5, 42.7, and 27.4%, in patients with PORT, respectively. Among the 27 patients with SCR, 16 (59.3%) patients developed SCR without DM ([Figure 1A](#F1){ref-type="fig"}) and 22 (81.5%) patients developed SCR involving the ipsilateral supraclavicular region ([Figure 1B](#F1){ref-type="fig"}). Moreover, among the 12 patients with left-lung cancer who developed SCR, seven were ipsilateral, three bilateral, and two contralateral. Among the 15 patients with right-lung cancer who developed SCR, nine were ipsilateral, three bilateral, and three contralateral.

![Patterns of supraclavicular recurrence. **(A)** Venn diagram demonstrating the distribution of initial postoperative recurrence. **(B)** Pie chart demonstrating the distribution of SCR. SCR, supraclavicular recurrence; LRR, loco-regional recurrence; DM, distant metastasis.](fonc-10-01414-g0001){#F1}

The 1, 3, and 5-year cumulative incidence of SCR were 6.53, 13.0, and 24.7%, respectively ([Figure 2A](#F2){ref-type="fig"}), and the dynamic of hazard ratio of SCR was presented in [Figure 2B](#F2){ref-type="fig"}. Chosen DM as a competing event, cN2 disease, ypN2, lobectomy, and CK7 were identified as significant risk factors of SCR using the univariate competing risk analysis ([Table 2](#T2){ref-type="table"}). Since there was a significant association between cN2 disease and receiving neoadjuvant chemotherapy (*p* \<0.001, χ^2^ test), we excluded cN2 disease and included the other three significant risk factors in the multivariate competing risk analyses. The result showed that only ypN2 were identified as an independent risk factor of SCR ([Table 2](#T2){ref-type="table"}). The 1, 3, and 5-year cumulative incidence of SCR were 24.90, 33.24, and 33.24% among ypN2 patients, respectively, and were 4.46, 10.67, and 22.69% among pN2 patients, respectively ([Figure 2A](#F2){ref-type="fig"}).

![Cumulative incidence and dynamics of supraclavicular recurrence. **(A)** Cumulative incidence of supraclavicular recurrence in the entire cohort and stratified by pathological status (ypN2 vs. pN2). **(B)** The dynamics of hazard ratio of supraclavicular recurrence.](fonc-10-01414-g0002){#F2}

###### 

Competing risk analyses of clinical-pathological variables associated with supraclavicular recurrence.

  **Variables**                                                 **Univariate Analyses**   **Multivariate Analyses**                       
  ------------------------------------------------------------- ------------------------- --------------------------- ------------------- -----------
  Age (\>65 vs. ≤ 65)                                           0.85 (0.40--1.81)         0.671                                           
  Sex (Male vs. Female)                                         1.23 (0.56--2.69)         0.604                                           
  Smoking (Never vs. Ever)                                      0.77 (0.35--1.69)         0.577                                           
  ECOG (1 vs. 0)                                                1.81 (0.62--5.26)         0.279                                           
  cN2 (+ vs. --)                                                2.58 (1.09--6.11)         **0.031**                                       
  pT stage (T3--4 vs. T0--2)                                    0.72 (0.22--2.41)         0.599                                           
  pN1 (+ vs. --)                                                0.83 (0.39--1.80)         0.643                                           
  Multiple levels of pN2 (+ vs. --)                             1.13 (0.53--2.42)         0.745                                           
  Histology (SCC vs. Non-SCC)                                   1.24 (0.50--3.07)         0.646                                           
  Differentiation (P vs. W/M)[^&^](#TN1){ref-type="table-fn"}   1.23 (0.57--2.65)         0.603                                           
  LVI (+ vs. --)                                                1.54 (0.72--3.31)         0.271                                           
  VPI (+ vs. --)                                                1.09 (0.49--2.43)         0.836                                           
  PNI (+ vs. --)                                                0.86 (0.20--3.64)         0.834                                           
  ypN2 vs. pN2                                                  4.61 (1.89--11.22)        **0.001**                   3.32 (1.30--6.50)   **0.012**
  Tumor Location (Left vs. Right)                               0.81 (0.38--1.73)         0.582                                           
  Tumor Lobe (Upper vs. Others)                                 1.25 (0.78--5.23)         0.374                                           
  TLN (≥16 vs. \<16)                                            0.60 (0.28--1.29)         0.190                                           
  PLN (≥3 vs. \<3)                                              0.95 (0.44--2.02)         0.885                                           
  LNR (≥0.2 vs. \<0.2)                                          1.88 (0.84--4.19)         0.123                                           
  Surgery (Others vs. Lobectomy)                                3.68 (1.61--8.42)         **0.002**                   1.32 (0.76--2.39)   0.319
  PORT (+ vs. --)                                               0.62 (0.27--1.43)         0.260                                           
  ERCC1 (+ vs. --)                                              0.90 (0.53--1.52)         0.695                                           
  Her2 (+ vs. --)                                               1.10 (0.67--1.78)         0.715                                           
  Ki67 (≥50 vs. \<50%)                                          1.81 (0.84--3.88)         0.129                                           
  TTF1 (+ vs. --)                                               0.64 (0.33--1.24)         0.181                                           
  CK20 (+ vs. --)                                               1.07 (0.67--1.70)         0.784                                           
  CK7 (+ vs. --)                                                0.32 (0.15--0.68)         **0.003**                   0.46 (0.19--1.13)   0.090
  CK5/6 (+ vs. --)                                              1.24 (0.77--2.01)         0.180                                           
  P63 (+ vs. --)                                                1.13 (0.66--1.93)         0.651                                           
  NapsinA (+ vs. --)                                            0.91 (0.50--1.64)         0.754                                           
  Syn (+ vs. --)                                                1.23 (0.71--2.57)         0.326                                           
  RRM1 (+ vs. --)                                               0.99 (0.58--1.69)         0.955                                           
  EGFR (+ vs. --)                                               0.98 (0.54--1.79)         0.946                                           

HR, hazard ratios; CI, confidence intervals; SCC, squamous cell carcinoma; LVI, Lymphovascular invasion; VPI, Visceral pleural invasion; PI, perineural invasion; ECOG, the Eastern Corporative Oncology Group; TLN, total lymph node examined; PLN, positive lymph node; LNR, positive lymph node ratio; PORT, postoperative radiotherapy;

*W/M, well/moderate; P, poor. Bold values indicates statistical significant*.

Pattern of Failure Analyses
---------------------------

In the entire cohort, 6 (6.38%) of the 94 patients who received PORT developed LRR, while 24 (11.1%) of the 217 patients who did not receive PORT developed LRR. PORT significantly reduced the risk of LRR ([Figure 3A](#F3){ref-type="fig"}). Among the six patients who received PORT and subsequently developed LRR, five developed LRR only within the PTV and the rest one developed LRR both within and outside the PTV. Among the 24 patients who did not receive PORT and subsequently developed LRR, 20 developed LRR only within the proposed PTV, three developed LRR both within and outside the proposed PTV, and the rest one developed LRR outside the proposed PTV. That patient had adenocarcinoma in the middle lobe of right lung, with pathologically proven metastatic lymph node in the right hilum and station 7, but developed recurrent disease at mediastinal lymph node stations 5 and 6.

![Prognostic significance of postoperative radiotherapy and supraclavicular recurrence. The impact of postoperative radiotherapy (PORT) on loco-regional recurrence (LRR) **(A)**, supraclavicular recurrence (SCR) **(B)**, overall survival (OS1) **(C)**, in the entire cohort. Kaplan--Meier survival curve stratified by the disease recurrence patterns among patients with recurrent disease **(D)**.](fonc-10-01414-g0003){#F3}

On the other hand, 8 (8.51%) of the 94 patients who received PORT developed SCR, while 19 (8.76%) of the 217 patients who did not receive PORT developed SCR in the entire cohort. PORT without ESRT didn\'t reduce the incidence of SCR ([Figure 3B](#F3){ref-type="fig"}). Fifteen of the 16 ipsilateral SCRs could be covered by the proposed PTV-sc and the ipsilateral parts of the six bilateral SCRs could all be covered by the proposed PTV-sc.

Survival Analyses
-----------------

By the time of data cut-off, 125 patients had died and the median OS1 was 49.0 (95CI 40.5--57.6) months. PORT was found to significant prolong OS1 in the entire cohort ([Figure 3C](#F3){ref-type="fig"}). Age, sex, ECOG score, lymphovascular invasion, total number of positive lymph node, positive lymph node ratio, PORT, and Ki67, were found to be significantly associated with OS1 in univariate Cox analyses, while age, ECOG score, PORT, and Ki67 were identified to be independent indicators of OS1 in multivariate Cox analyses ([Table 3](#T3){ref-type="table"}). Among the 203 patients with recurrent disease, the median OS2 was 19.0 (95CI 14.7--23.3) months. Age, sex, ECOG score, and DM were revealed to be significantly associated with OS1 in univariate and multivariate Cox analyses ([Table 4](#T4){ref-type="table"}).

###### 

Cox analyses of clinical-pathological variables associated with overall survival (OS1).

  **Variables**                                                 **Univariate Analyses**   **Multivariate Analyses**                       
  ------------------------------------------------------------- ------------------------- --------------------------- ------------------- -----------
  Age (\>65 vs. ≤ 65)                                           1.64 (1.14--2.15)         **0.008**                   1.46 (1.01--2.12)   **0.048**
  Sex (Male vs. Female)                                         1.49 (1.03--2.17)         **0.035**                   1.40 (0.94--2.08)   0.097
  Smoking (Never vs. Ever)                                      1.21 (0.85--1.73)         0.285                                           
  ECOG (1 vs. 0)                                                2.67 (1.71--4.19)         **0.001**                   2.22 (1.41--3.52)   **0.001**
  cN2 (+ vs. --)                                                1.11 (0.78--1.57)         0.575                                           
  pT stage (T3--4 vs. T0--2)                                    1.19 (0.74--1.90)         0.473                                           
  pN1 (+ vs. --)                                                1.51 (1.01--2.25)         0.042                                           
  Multiple levels of pN2 (+ vs. --)                             1.18 (0.83--1.67)         0.366                                           
  Histology (SCC vs. Non-SCC)                                   1.35 (0.88--2.08)         0.167                                           
  Differentiation (P vs. W/M)[^&^](#TN2){ref-type="table-fn"}   1.05 (0.80--1.24)         0.899                                           
  LVI (+ vs. --)                                                1.49 (1.04--2.12)         **0.028**                   1.21 (0.84--1.75)   0.297
  VPI (+ vs. --)                                                1.29 (0.90--1.85)         0.168                                           
  PNI (+ vs. --)                                                1.22 (0.70--2.14)         0.477                                           
  ypN2 vs. pN2                                                  0.76 (0.37--1.55)         0.445                                           
  Tumor Location (Left vs. Right)                               0.80 (0.56--1.14)         0.217                                           
  Tumor Lobe (Upper vs. Others)                                 1.17 (0.89--1.25)         0.913                                           
  TLN (≥16 vs. \<16)                                            0.92 (0.63--1.33)         0.644                                           
  PLN (≥3 vs. \<3)                                              1.46 (1.02--2.10)         **0.041**                   1.33 (0.80--2.21)   0.274
  LNR (≥0.2 vs. \<0.2)                                          1.44 (1.01--2.07)         **0.048**                   1.29 (0.78--2.13)   0.324
  Surgery (Others vs. Lobectomy)                                0.80 (0.43--1.49)         0.483                                           
  PORT (+ vs. --)                                               0.63 (0.42--0.93)         **0.020**                   0.61 (0.40--0.92)   **0.018**
  ERCC1 (+ vs. --)                                              1.03 (0.80--1.32)         0.825                                           
  Her2 (+ vs. --)                                               0.92 (0.72--1.16)         0.464                                           
  Ki67 (≥50 vs. \<50%)                                          1.65 (1.16--2.34)         **0.006**                   1.55 (1.06--2.25)   **0.023**
  TTF1 (+ vs. --)                                               0.81 (0.59--1.10)         0.181                                           
  CK20 (+ vs. --)                                               0.96 (0.76--1.20)         0.704                                           
  CK7 (+ vs. --)                                                0.75 (0.49--1.14)         0.178                                           
  CK5/6 (+ vs. --)                                              1.07 (0.85--1.35)         0.545                                           
  P63 (+ vs. --)                                                1.02 (0.80--1.32)         0.857                                           
  NapsinA (+ vs. --)                                            0.79 (0.60--1.05)         0.103                                           
  Syn (+ vs. --)                                                0.521 (0.23--1.41)        0.324                                           
  RRM1 (+ vs. --)                                               0.891 (0.62--1.42)        0.897                                           
  EGFR (+ vs. --)                                               0.82 (0.62--1.08)         0.155                                           

HR, hazard ratios; CI, confidence intervals; SCC, squamous cell carcinoma; LVI, Lymphovascular invasion; VPI, Visceral pleural invasion; PI, perineural invasion; ECOG, the Eastern Corporative Oncology Group; TLN, total lymph node examined; PLN, positive lymph node; LNR, positive lymph node ratio; PORT, postoperative radiotherapy;

*W/M, well/moderate; P, poor. Bold values indicates statistical significant*.

###### 

Cox analyses of clinical-pathological variables associated with OS2 in patients with recurrent disease.

  **Variables**                                                 **Univariate Analyses**   **Multivariate Analyses**                        
  ------------------------------------------------------------- ------------------------- --------------------------- -------------------- -------------
  Age (\>65 vs. ≤ 65)                                           1.70 (1.17--2.47)         **0.005**                   1.49 (1.02--2.19)    **0.040**
  Sex (Male vs. Female)                                         1.57 (1.07--2.30)         **0.020**                   1.74 (1.19--2.56)    **0.005**
  Smoking (Never vs. Ever)                                      1.23 (0.86--1.77)         0.260                                            
  ECOG (1 vs. 0)                                                1.95 (1.22--3.10)         **0.005**                   2.02 (1.25--3.26)    **0.004**
  cN2 (+ vs. --)                                                1.12 (0.78--1.61)         0.534                                            
  pT stage (T3--4 vs. T0--2)                                    1.15 (0.71--1.86)         0.572                                            
  pN1 (+ vs. --)                                                1.11 (0.74--1.65)         0.622                                            
  Multiple levels of pN2 (+ vs. --)                             0.89 (0.62--1.27)         0.517                                            
  Histology (SCC vs. Non-SCC)                                   1.56 (0.99--2.42)         0.051                                            
  Differentiation (P vs. W/M)[^&^](#TN3){ref-type="table-fn"}   1.04 (0.71--1.51)         0.851                                            
  LVI (+ vs. --)                                                1.35 (0.94--1.94)         0.104                                            
  VPI (+ vs. --)                                                1.07 (0.74--1.55)         0.732                                            
  PNI (+ vs. --)                                                0.96 (0.55--1.67)         0.875                                            
  ypN2 vs. pN2                                                  0.56 (0.28--1.16)         0.118                                            
  Tumor Location (Left vs. Right)                               1.05 (0.73--1.50)         0.810                                            
  Tumor Lobe (Upper vs. Others)                                 1.03 (0.79--2.17)         0.874                                            
  TLN (≥16 vs. \<16)                                            0.85 (0.65--1.42)         0.849                                            
  PLN (≥3 vs. \<3)                                              1.14 (0.78--1.65)         0.485                                            
  LNR (≥0.2 vs. \<0.2)                                          1.03 (0.72--1.50)         0.361                                            
  Surgery (Others vs. Lobectomy)                                1.45 (0.76--2.77)         0.266                                            
  PORT (+ vs. --)                                               0.85 (0.66--1.23)         0.414                                            
  DM (+ vs. --)                                                 6.49 (2.36--17.85)        **\<0.001**                 7.43 (2.67--20.68)   **\<0.001**
  ERCC1 (+ vs. --)                                              1.04 (0.81--1.33)         0.765                                            
  Her2 (+ vs. --)                                               0.83 (0.65--1.07)         0.152                                            
  Ki67 (≥50 vs. \<50%)                                          1.19 (0.83--1.70)         0.356                                            
  TTF1 (+ vs. --)                                               0.73(0.53--1.02)          0.061                                            
  CK20 (+ vs. --)                                               0.92 (0.72--1.16)         0.472                                            
  CK7 (+ vs. --)                                                0.87 (0.63--1.20)         0.403                                            
  CK5/6 (+ vs. --)                                              1.01 (0.80--1.27)         0.955                                            
  P63 (+ vs. --)                                                0.91 (0.71--1.18)         0.484                                            
  NapsinA (+ vs. --)                                            0.76 (0.57--1.02)         0.063                                            
  Syn (+ vs. --)                                                1.37 (0.92--2.35)         0.781                                            
  RRM1 (+ vs. --)                                               0.97 (0.71--1.42)         0.971                                            
  EGFR (+ vs. --)                                               0.84 (0.64--1.11)         0.226                                            

OS, overall survival; HR, hazard ratios; CI, confidence intervals; SCC, squamous cell carcinoma; LVI, Lymphovascular invasion; VPI, Visceral pleural invasion; PI, perineural invasion; ECOG, the Eastern Corporative Oncology Group; TLN, total lymph node examined; PLN, positive lymph node; LNR, positive lymph node ratio; PORT, postoperative radiotherapy; DM, distant metastasis;

*W/M, well/moderate; P, poor. Bold values indicates statistical significant*.

In order to investigate the prognostic significance of SCR, patients with recurrent disease were further divided into three groups: Group A consisted of patients who had DM (*n* = 178), Group B consisted of patients who did not have DM but have SCR (*n* = 16), and Group C consisted of patients who only had LRR (*n* = 9). In terms of OS2, patients in Group B had an intermediate prognosis, when compared with patients in Group A and Group C ([Figure 3D](#F3){ref-type="fig"}).

Discussion {#s4}
==========

To the best of our knowledge, this is the first comprehensive study specifically focusing on SCR in completely resected (y)pN2 NSCLC with a relatively large sample size, in the era of modern radiation technique. SCR was not uncommon and had imperative prognostic significance, indicating that treatment modalities able to reduce the incidence of SCR may be beneficial. Additionally, PORT without ESRT significantly reduced LRR and prolonged OS, but did not decrease SCR in our study, suggesting that the clinical value of ESRT may be reconsidered in selected patients with high risks of SCR.

SCR is not uncommon in completely resected (y)pN2 NSCLC, especially among those with extra risk factors. Although there was limited historical data published that could be directly compared, the incidence of SCR in our study was reliable, since the overall recurrence rate and the percentage of SCR among patients with recurrent disease were in accordance with previous findings. The cumulative incidence of postoperative recurrence in the PORT group and non-PORT group, were generally comparable with recent studies ([@B7], [@B9], [@B17], [@B23]). Furthermore, studies from our institution ([@B7]) and others ([@B16], [@B24]) had reported a similar percentage of SCR among patients with recurrent disease (7.7--11.6% in the literature, 13.3% in our study). Compared with their counterpart, patients staged cN2 or ypN2 generally had a more advanced and aggressive disease, and thus it was reasonable for them to have a higher risk developing disease recurrence, including SCR ([@B17], [@B25]--[@B27]). Compared with those receiving lobectomy, patients receiving pneumonectomy generally had a higher tumor burden and those receiving sublobectomy commonly had unfavorable prognostic factors, such as more comorbidities and poorer preoperative lung functions, that made them unsuitable for lobectomy ([@B23], [@B28]). Therefore, patients who didn\'t receive lobectomy were also at a higher risk developing postoperative recurrence, which is generally consistent with a recent retrospective study using the SEER database ([@B29]). In addition, two recent studies found that positive expression of CK7 were associated with more advanced disease and shorter overall survival ([@B30], [@B31]). In our study, distant metastasis was chosen as a competing event and negative expression of CK7 was identified as a risk factor of SCR, which need to be further verified.

Compared with patients developing only LRR and those developing DM, patients developing SCR but without DM had intermediate OS2, highlighting the vital prognostic significance of SCR in curatively resected (y)pN2 NSCLC. The TNM staging system is one of the most powerful indicators of patient\'s prognosis in NSCLC, among which patients having supraclavicular lymph node metastasis (N3) generally have intermediate prognosis when compared with those having distant metastasis (M1) and those harboring metastatic tumor lesions limited to the ipsilateral hilar (N1) or mediastinal (N2) lymph nodes ([@B20]). Similarly, SCR represented an unfavorable sign of subsequent disease metastasis to distant organs and thus was reasonable to have worse prognosis when compared with those who had only LRR. On the other hand, when compared with those who already had DM, patients who had recurrent disease limited to the thoracic region (i.e., LRR and SCR) could be considered as harboring loco-regional disease and may benefit from aggressive loco-regional treatment, as well as systematic therapies, and thus may still have a chance of long-term survival ([@B32]). In fact, among the 16 patients with SCR but without DM, the 3-year survival rate exceeded 70% in our study ([Figure 3D](#F3){ref-type="fig"}). However, due to the advancement of adjuvant chemotherapy and PORT, the number of patients who developed localized recurrent disease (i.e., LRR and SCR) was small (16 patients in group B and 9 patients in group C), although a total of 311 patients were enrolled and followed up for a median of 26 months. Hence, the prognostic significance of SCR needed to be interpreted with caution and future investigations with larger sample size and prospective design are warranted.

The clinical value of PORT in completely resected (y)pN2 NSCLC was demonstrated again in our study, but the delineation of CTV remain controversial. In the current study, PORT significantly reduced LRR and improved OS1, which have been demonstrated in various studies ([@B5], [@B6], [@B8]--[@B11], [@B16], [@B17], [@B23]). However, since ESRT was not routinely performed in our cancer institution ([@B7]), PORT failed to reduce SCR, indicating that the majority of SCRs represented the outgrowth of subclinical tumor lesions already in the supraclavicular region and were not originated from the loco-regional recurrent disease through lymphatic metastasis. In fact, 19 (70.4%) of the 27 patients with SCR had no LRR in the current study. These data indicated a potential role of ESRT in selected patients with high risks. Actually, for locally advanced NSCLC receiving chemo-radiotherapy, there is no significant difference of patient\'s survival between those with or without N3 disease ([@B33], [@B34]), highlighting that the treatment efficacy of chemo-radiotherapy in locally advanced NSCLC was largely dependent on the intrinsic biology of the tumor and the prognosis of patients with or without macroscopic supraclavicular tumor lesions seemed similar. PORT with adjuvant chemotherapy has been repeatedly shown to significantly reduce LRR, indicating the beneficial role of adjuvant chemo-radiotherapy in treating microscopic N1/N2 disease. It is possible that adjuvant chemo-radiotherapy (i.e., adjuvant chemotherapy in combination with ESRT) may also play a role in reducing SCR and subsequently improve patient\'s survival. Furthermore, nearly 70% of the ipsilateral SCRs could be covered with the virtual CTV of ESRT in our study. However, there are also evidence against the use of ESRT for patients with completely resected NSCLC. Elective irradiation of mediastinal, contralateral hilar and supraclavicular lymph nodes failed to improve patient\'s survival in unresectable stage III NSCLC without clinical N3 disease ([@B35]). And pattern of failure analyses of a prospective trial of PORT without ESRT suggested that the use of limited CTV including only the involved lymph node stations and those with a risk of invasion \>10%, was associated with acceptable risk of geographic miss ([@B36]). Taken together, PORT without ESRT provided significant clinical benefit for patients with completely resected (y)pN2 NSCLC, and the clinical value of ESRT in highly selected patients, for example those with persistent N2 (ypN2) disease after neoadjuvant chemotherapy, need to be further investigated.

Our study also has some limitations. Firstly, since ESRT is not routinely performed in our cancer center, we could not directly examine the clinical value and prognostic significance of ESRT. Secondly, as this was a retrospectively study, treatment decisions and follow-up strategies were at the discretion of the treating physicians. Different neoadjuvant and adjuvant chemotherapy regimens were used and the protocols of follow-up were not identical. Moreover, since brain MRI and bone scans were not mandatory, asymptomatic brain and/or bone metastasis may be underestimated. Despite these limitations, we believe our study provided valuable information about the cumulative incidence and prognostic significance of SCR in completely resected (y)pN2 NSCLC, which may guide better design of adjuvant treatment modalities and individualized surveillance strategies.
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